Business Context and Reporting Period
This Form 8-K filing by Moderna, Inc. (MRNA) covers events occurring on May 3, 2019, and the announcement of financial results for the first quarter ended March 31, 2019, issued on May 8, 2019. Moderna is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the results of operations and financial condition for the first quarter of 2019. However, this specific 8-K text does not provide numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the referenced press release or the upcoming Form 10-Q for specific financial data.
Material Changes and Agreements
On May 3, 2019, Moderna entered into a Fifth Amendment to its Collaboration and License Agreement with Merck Sharp & Dohme Corp. Key changes include:
- New Product Candidate: Merck elected to establish mRNA-1172 as a new product candidate for the prevention of respiratory syncytial virus (RSV) infection and will conduct a Phase 1 clinical trial.
- Cost and Milestone Structure: Moderna will bear certain costs for the mRNA-1172 Phase 1 trial and is eligible for an additional milestone payment, contingent on Merck continuing development.
- Pediatric Rights: Moderna retains the right to research, develop, and commercialize RSV prevention candidates for the pediatric population.
- Scope Reduction: The collaboration with Merck will now focus exclusively on RSV. Development of candidates for other viruses, including mRNA-1278 for varicella zoster virus (VZV), is discontinued.
- Paused Development: Further development of the original RSV candidate, mRNA-1777, has been paused pending data from the new mRNA-1172 trial.
Outlook, Risks, and Management Commentary
Management commentary is limited to the strategic shift in the Merck collaboration. The filing notes that the full terms of the Collaboration Amendment will be filed as an exhibit to the Quarterly Report on Form 10-Q for the quarter ending June 30, 2019. No specific forward-looking guidance, risk factors, or unusual items are detailed within the text of this 8-K beyond the operational changes described above.
Investor Verification Checklist
- Verify the specific financial results for Q1 2019 in the press release (Exhibit 99.1) referenced in Item 2.02.
- Review the full text of the Fifth Amendment to the Merck Collaboration Agreement once filed as an exhibit to the Q2 2019 Form 10-Q.
- Monitor the progress and data readouts of the Phase 1 clinical trial for mRNA-1172.
- Confirm the status of the paused mRNA-1777 development program based on future trial data.
